Kenvue Inc. (NYSE:KVUE) Shares Bought by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. raised its position in Kenvue Inc. (NYSE:KVUE) by 8.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 23,652 shares of the company’s stock after acquiring an additional 1,748 shares during the period. Global X Japan Co. Ltd.’s holdings in Kenvue were worth $547,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in KVUE. Manchester Capital Management LLC raised its holdings in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the last quarter. Mather Group LLC. purchased a new position in shares of Kenvue in the first quarter valued at $28,000. Riverview Trust Co acquired a new position in shares of Kenvue during the 3rd quarter worth $30,000. MV Capital Management Inc. boosted its position in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after buying an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in Kenvue in the 1st quarter valued at about $33,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research reports. Jefferies Financial Group initiated coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Sandler lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. UBS Group raised their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $22.93 on Wednesday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.55. The firm has a market cap of $43.91 billion, a P/E ratio of 29.40, a PEG ratio of 2.76 and a beta of 1.40. The stock has a fifty day moving average price of $22.33 and a two-hundred day moving average price of $20.24. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same period in the previous year, the company earned $0.32 earnings per share. Kenvue’s revenue was down .3% compared to the same quarter last year. Research analysts forecast that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.58%. Kenvue’s dividend payout ratio (DPR) is 105.13%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.